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Abstract
Purpose of the Review Opioid use disorder in the USA is
rising at an alarming rate, particularly among women of child-
bearing age. Pregnant women with opioid use disorder face
numerous barriers to care, including limited access to treat-
ment, stigma, and fear of legal consequences. This review of
opioid use disorder in pregnancy is designed to assist health
care providers caring for pregnant and postpartum women
with the goal of expanding evidence-based treatment practices
for this vulnerable population.
Recent Findings We review current literature on opioid use
disorder among US women, existing legislation surrounding
substance use in pregnancy, and available treatment options
for pregnant women with opioid use disorder. Opioid agonist
treatment (OAT) remains the standard of care for treating opi-
oid use disorder in pregnancy. Medically assisted opioid
withdrawal (Bdetoxification^) is not recommended in preg-
nancy and is associated with high maternal relapse rates.
Extended release naltrexone may confer benefit for carefully
selected patients. Histories of trauma and mental health disor-
ders are prevalent in this population; and best practice recom-
mendations incorporate gender-specific, trauma-informed,
mental health services. Breastfeeding with OAT is safe and
beneficial for the mother-infant dyad.
Summary Further research investigating options of OAT and
the efficacy of opioid antagonists in pregnancy is needed. The
US health care system can adapt to provide quality care for
these mother-infant dyads by expanding comprehensive treat-
ment services and improving access to care.
Keywords Pregnancy . Opioid use disorder . Opioid agonist
treatment .Naltrexone .Trauma-informedcare .Mentalhealth
disorder . Breastfeeding
Introduction
Over the last decade, prescription opioid misuse and illicit
heroin use have skyrocketed, and overdose deaths have qua-
drupled [1]. From 2002 to 2013, the largest increase in heroin
use was among women [2]. A 2014 SAMHSA report showed
female treatment admissions for opioid pain relievers as the
primary substance of abuse outnumber male admissions in all
age categories [3]. The rate of opioid use during pregnancy is
approximately 5.6 per 1000 live births [4], with one study
reporting greater than 85 % of pregnancies in women with
opioid use disorder were unintended [5]. Given the high rates
of opioid use among USwomen of childbearing age, and high
incidence of unintended pregnancy in those with opioid use
disorder, obstetric providers will need to be prepared to care
for this growing demographic.
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Despite the increasing acceptance of substance use disorder
as a chronic illness, only 11 % of the 24 million Americans
with substance use disorder receive treatment [6], and stigma
remains a significant barrier to treatment. For pregnant wom-
en, this is especially potent. Barriers to care include lack of
access to gender-specific care, limited child-care availability
at treatment facilities [7], few providers with obstetrics and
addiction treatment expertise [8], increased social stigma,
and fear of criminal or child welfare consequences. Only 19
states have funded drug treatment programs specifically de-
signed for pregnant women, and 12 states provide pregnant
women with priority access to treatment programs.
State policies regarding the response to and reporting of
substance use disorder in pregnancy vary wildly. Recently in
some states, policymakers have debated legislation criminal-
izing pregnant women with substance use disorders. In 2014,
Tennessee became the first state to pass a law criminalizing
illicit drug use during pregnancy.1 Eighteen states require
health care professionals to report suspected prenatal use of
illicit substances, four require health care professionals to test
for prenatal drug exposure if substance use disorders are
suspected, and 18 states consider substance abuse during preg-
nancy to be child abuse under civil child-welfare status [9].
Low-income women and women of color are at higher risk
for barriers to appropriate care of substance use disorders dur-
ing pregnancy, in part explaining the poor perinatal outcomes
associated with this population [10]. One study found a clear
association between little or no prenatal care and opioid use,
with a cohort of postpartum patients reporting external locus
of control, fear of being reported to the police, and disbelief in
the efficacy of care as factors [11].
In the context of rising opioid deaths and increased atten-
tion from policymakers, the Department of Health and Human
Services has suggested three strategies to reduce deaths: safe
prescribing, expansion of medication treatment, and expan-
sion of naloxone access.
In the following review, we will address pharmacologic
treatment options for pregnant women with opioid use disor-
der, with special consideration of mood disorders, trauma his-
tory, and breastfeeding.
Should Pregnant Women with Opioid Use Disorder
Undergo BDetoxification^?
Opioid withdrawal (detoxification) in pregnancy is complex
and has both risks associated with withdrawal and of relapse
for the mother and the fetus. Current practice recommenda-
tions are to avoid opioid withdrawal (detoxification) as the
benefits of opioid agonist treatment (OAT) for the mother
and the fetus exceed the risks [12]. This recommendation
was originally based on a few case studies from the 1970s
associating opioid withdrawal with fetal death, miscarriage,
and preterm labor [13–15].
Retrospective studies have attempted to evaluate the risk of
fetal loss with maternal opioid withdrawal. Luty et al. con-
cluded opioid withdrawal in the first trimester may be associ-
ated with miscarriage but that it was likely safer in the second
and third trimesters [16]. Several studies evaluating opioid
withdrawal in pregnancy have not shown significant risk of
fetal loss, often with miscarriage rates comparable to popula-
tion norms [17, 18, 19•, 20]. Unfortunately, these studies are
underpowered and contain confounders making the risk of
pregnancy loss secondary to opioid withdraw difficult to
quantify.
Maternal opioid withdrawal does decrease incidence and
duration of neonatal abstinence syndrome [17, 18]. Despite
recent studies suggesting fetal safety of medically assisted
opioid withdrawal in pregnancy, abstinence of maternal drug
use was low and maternal relapse rates range from 59 to 99 %
[18, 19•].
We believe opioid withdrawal is an inferior option com-
pared to OAT for pregnant women, and risk of maternal re-
lapse, with inherent overdose mortality risk, outweighs the
potential reduction in NAS. In the general population, OAT
is the standard of care for opioid use disorder; a standard
which should not be altered by pregnancy.
Treatment Options for Pregnant Women: Opioid Agonist
Treatment
OAT is the first-line recommendation for pregnant women
with opioid use disorders. The goals of treatment are to man-
age withdrawal, reduce cravings, and provide opioid blockade
(preventing euphoria from illicit use). The goals of OAT in
pregnancy are to prevent illicit opioid use which can increase
the risk of fetal growth restriction, abruptio placentae, fetal
death, preterm labor, and intrauterine passage of meconium.
OAT has been shown to increase adherence to prenatal care,
reduce illicit drug use, reduce infection exposure secondary to
IVDU, such as HIV, HCV, HCB, improve maternal nutrition,
and improve infant birth weight [21].
Neonatal abstinence syndrome (NAS) is an expected and
treatable condition due to prenatal opioid exposure. Forty to
80 % of exposed neonates develop withdrawal requiring hos-
pitalization and pharmacotherapy. Historically, methadone
has been the gold standard OAT choice for pregnant women.
Emerging evidence supports the use of buprenorphine as an
effective therapeutic option in pregnancy and shows improved
neonatal outcomes. A 2010 multicenter randomized clinical
trial showed buprenorphine-exposed neonates required, on
average, 89 % less morphine to treat NAS, a 43 % shorter
1 Due to opposition from health care professionals and patient advocacy
groups, this law is currently being repealed.
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hospital stay, and a 58% shorter duration of medical treatment
for NAS compared to methadone-exposed newborns. These
results support the use of buprenorphine as a potential first-
line medication for pregnant opioid-dependent women [22••].
The advantages of buprenorphine over methadone include
a lower risk of overdose, fewer drug interactions, office-based
treatment delivery, and shorter NAS course. The disadvan-
tages compared with methadone include potential hepatic dys-
function, lack of long-term data on consequences of fetal ex-
posure for the infant, potential limited efficacy in patients with
high opioid debt, requirement of moderate withdrawal symp-
toms prior to initiation to avoid iatrogenic withdrawal, and an
increased risk of diversion (i.e., sharing or sale) [21]. To date,
studies have not assessed the impact of maternal opioid addic-
tion severity on newborn outcomes and maternal long-term
recovery.
For the provider, the choice of OAT type to initiate must be
individualized and is often restricted by availability and access
to services. We recommend, whenever possible, to optimize
patient autonomy in this decision. Despite buprenorphine’s
neonatal advantages, it will not be effective for all women.
We suggest the best neonatal outcomes will be achieved by
providing the most appropriate and effective treatment for the
mother.
Overdose and the Use of Naloxone in Pregnancy
Currently, opioid overdose is a leading cause of death in
Americans 25–45 years of age. Education and expansion of
access to naloxone is one evidence-based strategy to address
this issue. No study has looked at pregnancy outcomes in
patients treated with naloxone for acute opioid overdose, but
the use of naloxone for resuscitation in overdose should not be
withheld out of concern for the developing fetus. Despite po-
tential negative effects of acute opioid withdrawal on the fetus,
including stillbirth, fetal distress, and premature labor [18],
prevention of maternal death from opioid overdose is the
priority.
Extended Release Naltrexone Use in Pregnancy
Naltrexone (pregnancy category C) is a non-selective opioid
receptor antagonist which has shown promise in treating opi-
oid use disorders by decreasing drug-seeking behaviors, drug
cravings, and increasing treatment retention [23–25].
Naltrexone has the potential to treat select opioid-dependent
pregnant women while eliminating the risk of neonatal absti-
nence syndrome; however, limited human data are available
on naltrexone’s safety and efficacy in pregnancy. Animal stud-
ies using 175 times the recommended human dosing have not
shown teratogenic effects [26]. Opioid receptors in fetal
mammalian tissue exposed to exogenous opioids or opioid
antagonists may alter neurobiology and growth [27]. Studies
of human-equivalent dosing of implantable naltrexone in ro-
dents show no changes in offspring’s brain morphometry.
Behavioral changes in these naltrexone-exposed offspring
suggest possible alterations in morphine receptor sensitivity
which may persist [28]. Case reports of depot naltrexone ex-
posure in humans have not shown teratogenic effects [29], and
in comparison with MMT, it shows lower PTD rates, higher
birth weights, and improved APGAR scores. No significant
differences in gestational age at birth or birth weight have been
noted between non-exposed human neonates and naltrexone
implant exposed [30]. Naltrexone does not demonstrate toler-
ance mitigating the need for increase doses in pregnancy [31].
Induction of depot naltrexone during pregnancy is a com-
plicated proposal and is not currently recommended. OAT
remains the standard of care in pregnancy due to improved
adherence to addiction treatment services, prenatal care, and
in-hospital delivery [19•]. However, women who are stable on
extended release naltrexone who become pregnant, based on
human and animal data available to date, could be reasonably
continued on naltrexone through pregnancy. Individualized
treatment plans weighing the risk of altering therapy (stopping
naltrexone) and potential destabilization of maternal recovery
must be considered. The risk of relapse and possible overdose
with such an alteration in addiction treatment may significant-
ly outweigh the naltrexone exposure risk to the fetus alone.
Future research on in utero exposure and perioperative pain
management of extended release naltrexone are needed [32•].
Special Considerations: Trauma, Mood Disorders,
Breastfeeding
Trauma and Substance Use Disorder in Women
Prior traumatic experiences from exposure to physical, sexual,
and emotional abuse are common among women with sub-
stance use disorder, with estimates ranging from 50 to 80 %
[33–35]. Pregnancy can be a vulnerable and triggering time
for women with trauma histories. A recent qualitative study by
Torchalla et al. of pregnant and newly parenting women with
substance use disorder in Vancouver identified that all women
reported childhood adversity and 77 % reported prior sexual
abuse [36]. This study identified themes of continued adverse
experiences persisting into adulthood and high rates of inti-
mate partner violence during pregnancy. Women expressed
concern over the possible trans-generational effects of their
trauma on their infants, but the majority of women questioned
had not received any trauma-specific services, and many
expressed ambivalence or reluctance in participating in trauma
counseling.
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Trauma-informed care, or the principle that service deliv-
ery is designed with an understanding of the impact of victim-
ization and trauma, has becomemore prevalent as a method to
care for women in gender-specific substance use treatment
programs [37, 38]. Yet, a recent secondary database review
from publicly available data sets by Terplan et al. examined
13,000 addiction treatment facilities in the USA and found
that trauma-related services were selectively available in ur-
ban centers and states with larger populations, and a large
percentage of women in treatment programs reported unmet
needs [39•]. A case study by Goodman et al. examined the
complexities of providing obstetric care for women with co-
morbid PTSD and substance use and stressed the importance
of early screening and a coordinated multidisciplinary ap-
proach to improving outcomes for the substance-exposed
mother-infant dyad [40].
Mood Disorders in Women with Opioid Use Disorders
According to the National Survey of Substance Abuse
Treatment Services, 45 % of Americans seeking treatment
for substance use disorders have co-occurring mental health
disorders, specifically depression and anxiety [41].
Infants of untreated, depressed mothers demonstrate re-
duced scores for motor adaptation and self-regulation, have
higher arousal scores, are more difficult to console, and can
exhibit developmental delay and poor neonatal attachment
[42–44].
Several well-conducted reviews demonstrate the safety of
selective serotonin reuptake inhibitors (SSRIs) in pregnancy,
with the exception of paroxetine, which may increase the risk
of cardiac defects [27]. The most common and the best
established adverse effect of SSRIs is poor neonatal adapta-
tion (PNA); PNA is prolonged when SSRIs are combined
with benzodiazepines [45]. In addition, SSRIs in combination
with opioids have been shown to worsen severity of NAS [46,
47].
The decision of when and how to treat perinatal depression
is a complex risk-benefit algorithm. Mild to moderate depres-
sion should probably be treated with cognitive behavioral
therapy or interpersonal therapy (if available). The studies
supporting this are small but CBTand IPTare proven effective
treatments for depression [48].
For anxiety disorders, SSRIs should be considered the first-
line pharmacotherapy. Benzodiazepines are relatively contra-
indicated in women with opioid use disorders. For patients on
OAT, benzodiazepines exacerbate the sedating effect of meth-
adone and increase accidental injury, especially in women
prescribed with buprenorphine [49]. Neonates exposed in
utero to both OATand benzodiazepines experience prolonged
NAS [46]. The authors caution that benzodiazepine use disor-
der and benzodiazepine diversion are growing public health
concerns and recommend vigilance in prescribing practice.
Breastfeeding and OAT in Pregnancy
Breastfeeding is recommended for women on OAT.
Methadone and buprenorphine are both lactation category C
and transferred via the breast milk but in amounts <1 % of the
maternal dose [50–53]. Published guidelines from the
American Academy of Pediatrics (AAP), the American
College of Obstetricians and Gynecologists (ACOG), and
the Academy of Breastfeeding Medicine (ABM) all support
breastfeeding for women stabilized on OAT [54–56]. The
2015 ABM statement includes criteria for encouraging
breastfeeding among mothers with the following: (1) compli-
ance with a substance use disorder treatment program, (2)
consistent prenatal care, (3) negative urine toxicology screen
Table 1 Recommendations for health care systems to provide to pregnant women with opioid use disorder
oAccess to opioid agonist treatment options
Methadone or buprenorphine
oAccess to obstetric care
Recovery-affirming and trauma-informed
Comprehensive obstetric and addiction medicine services
Group prenatal care as an option
oAccess to psychiatry consultation: assessment and treatment options for co-occurring disorders
oAccess to behavioral health counseling: weekly individual or group counseling
oResource guides for community-based relapse prevention
Mutual aid support groups
Mothers-in-recovery groups
oDevelopment of enhanced postpartum care: program development to intensify recovery support potentially utilizing peer supports
Close follow-up (<2 weeks from delivery)
Allow for multiple postpartum visits
Consider visits every 2 weeks for 3–6 visits
Breastfeeding/lactation support
Screening/treatment for postpartum depression
Transition to a primary care provider familiar with opioid use disorder and its treatment
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at the time of delivery, and (4) negative urine screens for 30–
90 days prior to delivery [54]. One institution expanded on the
ABM criteria by (1) defining consistent prenatal care as atten-
dance of at least 50 % of scheduled visits, including two visits
within the last 2 months, and (2) creating a B4-week
guideline^ of no positive urine drug screens for breastfeeding
initiation, leading to subsequent improved breastfeeding rates
[57]. The use of prenatal urine drug screens as a predictor
for postpartum recovery remains unknown despite these
recommendations.
For women on OAT, breastfeeding can be a complex issue.
Despite AAP, ACOG, and ABM statements endorsing the
benefits of breastfeeding on OAT and its safety with
coexisting hepatitis C status, policies differ among institu-
tions. Policies may reflect provider fear of maternal relapse,
concern for concurrent psychiatric medications, and how these
may complicate the course of NAS [58–60]. However, numer-
ous studies have shown a strong association between
breastfeeding and improved NAS symptoms, with reduction
in need for pharmacotherapy and shortened hospitalizations
[61–64]. In addition, there are significant maternal benefits
including reinforcing sobriety, enhancingmaternal self-esteem,
and the promoting mother-infant bonding. Previous studies
have not differentiated between direct breastfeeding and
pumped breast milk, nor mixed feeding versus exclusive
breastfeeding. The benefit is likely related to maternal presence
at the bedside, skin-to-skin contact, and engagement in care.
Conclusion
Over the past 10 years, there has been a surge of illicit opioid
use in the USA. Pregnant women with opioid use disorder are
at an increased risk for negative birth outcomes. Limited ac-
cess to care, social stigma, inadequate insurance coverage, and
fear of legal consequences are some of the many barriers to
care for pregnant women. The current standard of care for
opioid use disorder in pregnancy is an opioid agonist treat-
ment. Assisted opioid withdrawal is not recommended due to
the high risk of relapse. Extended release naltrexone is a viable
option for carefully selected women. With further study, the
use of buprenorphine + naloxone (dual-therapy) may replace
treatment with buprenorphine (mono-therapy) in pregnancy.
Opioid use disorder treatment should be gender specific, and
prenatal care programs should incorporate trauma-informed
care and provide mental health services. Initiation of pharma-
cologic treatment for mental health disorders must consider
maternal efficacy, maternal and fetal safety, and risk of NAS
potentiation. Breastfeeding for women on OAT is safe and
should be supported to decrease onset, duration, and severity
of NAS.
In our current healthcare system, the expansion of safe,
effective, and dignified multidisciplinary treatment options
for pregnant women with opioid use disorders is greatly need-
ed. Expansion of access to care for pregnant women can be
achieved by increasing the number of buprenorphine-
waivered obstetric providers and expanding comprehensive
obstetric and addiction medicine models of care. Obstetric
providers must strive to decrease the stigma associated with
the disease, reduce the barriers to care, and implement com-
prehensive programs to meet the rising demand.
Our recommendations for health care systems to provide to
pregnant women with opioid use disorder can be found in
Table 1.
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